Consistent with these genomic observations, abundant pre-clinical evidence across many malignancies indicates that BRAF alterations drive an increase in MAPK signaling and, thus, tumor growth in cancer cell lines and transgenic mouse models [20–22]. This evidence concerns the gene BRAF and neoplasm.